These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 31020929

  • 1. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM, Gong Y, Shaw KM, Bian J, Song WL, Linton MF, Fonseca V, Price-Haywood E, Guhl E, King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez AF, Cooper-DeHoff RM.
    J Am Heart Assoc; 2019 May 07; 8(9):e011246. PubMed ID: 31020929
    [Abstract] [Full Text] [Related]

  • 2. The PCSK9 revolution: Current status, controversies, and future directions.
    Warden BA, Fazio S, Shapiro MD.
    Trends Cardiovasc Med; 2020 Apr 07; 30(3):179-185. PubMed ID: 31151804
    [Abstract] [Full Text] [Related]

  • 3. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.
    Colivicchi F, Massimo Gulizia M, Arca M, Luigi Temporelli P, Gonzini L, Venturelli V, Morici N, Indolfi C, Gabrielli D, De Luca L.
    Cardiovasc Ther; 2020 Apr 07; 2020():3856242. PubMed ID: 31969932
    [Abstract] [Full Text] [Related]

  • 4. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT, Hochfellner DA, Knoll L, Pöttler T, Mader JK, Aberer F.
    Cardiovasc Diabetol; 2021 Apr 24; 20(1):89. PubMed ID: 33894772
    [Abstract] [Full Text] [Related]

  • 5. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.
    Circ Cardiovasc Qual Outcomes; 2018 May 24; 11(5):e004652. PubMed ID: 29748356
    [Abstract] [Full Text] [Related]

  • 6. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V.
    Circulation; 2016 Nov 29; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R.
    Eur J Prev Cardiol; 2018 May 29; 25(8):844-853. PubMed ID: 29569492
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. LDL cholesterol: How low to go?
    Packard CJ.
    Trends Cardiovasc Med; 2018 Jul 29; 28(5):348-354. PubMed ID: 29336946
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 13. PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.
    Paciullo F, Momi S, Gresele P.
    Thromb Haemost; 2019 Mar 19; 119(3):359-367. PubMed ID: 30605918
    [Abstract] [Full Text] [Related]

  • 14. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 19; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 15. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD, Aday AW, Rose LM, Ridker PM.
    Circulation; 2018 Jul 10; 138(2):141-149. PubMed ID: 29716940
    [Abstract] [Full Text] [Related]

  • 16. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
    Handelsman Y, Lepor NE.
    J Am Heart Assoc; 2018 Jun 22; 7(13):. PubMed ID: 29934421
    [No Abstract] [Full Text] [Related]

  • 17. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
    Myers KD, Farboodi N, Mwamburi M, Howard W, Staszak D, Gidding S, Baum SJ, Wilemon K, Rader DJ.
    Circ Cardiovasc Qual Outcomes; 2019 Aug 22; 12(8):e005404. PubMed ID: 31331194
    [Abstract] [Full Text] [Related]

  • 18. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C, Kelly MS, Shapiro MD, Dixon DL.
    J Cardiovasc Pharmacol; 2020 May 22; 75(5):410-420. PubMed ID: 32379108
    [Abstract] [Full Text] [Related]

  • 19. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
    Navar AM, Mulder HM, Wojdyla DM, Peterson ED.
    Circ Cardiovasc Qual Outcomes; 2020 Jan 22; 13(1):e006019. PubMed ID: 31918581
    [No Abstract] [Full Text] [Related]

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 22; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.